Subscribe to RSS
DOI: 10.1055/s-0030-1262421
© Georg Thieme Verlag KG Stuttgart · New York
Amiodaron-induzierte Leberfunktionsstörungen
Amiodarone-induced liver dysfunctionsPublication History
eingereicht: 4.1.2010
akzeptiert: 29.4.2010
Publication Date:
29 June 2010 (online)

Zusammenfassung
Amiodaron, ein dijodiertes Benzofuranderivat, wird überwiegend zur Therapie supraventrikulärer und ventrikulärer Arrhythmien eingesetzt. Die Amiodaronkonzentration in der Leber kann bis zu 500-fach höher liegen als die Serumkonzentration. Aufgrund der sehr langen Halbwertszeit und ausgeprägter Lipophilie ist Amiodaron im Serum noch Monate nach Beendigung der Therapie nachweisbar, und seine Akkumulation in der Leber kann dazu führen, dass ein eventueller Leberschaden auch nach Absetzen der Therapie fortschreitet. Die pathophysiologischen Grundlagen der Amiodaron-induzierten Leberfunktionsstörungen sowie deren klinische Implikationen werden in der folgenden Übersicht dargestellt.
Abstract
Amiodarone, a diiodinated benzofuran derivative, is widely used for treating ventricular and supraventricular tachyarrhythmias. Amiodarone is highly lipophilic and accumulation in the liver can be 500 times higher than serum amiodarone levels. Due to a long half-life and the lipophilic properties, the stored drug is capable of damaging the liver long after the drug has been stopped. Serious liver damage can lead to acute liver failure, cirrhosis and the need for liver transplantation. In this article we describe amiodarone-induced liver dysfunction and the diagnostic and therapeutic challenges in patients on amiodarone.
Schlüsselwörter
Vorhofflimmern - Amiodaron - Hepatoxizität
Keywords
atrial fibrillation - amiodaron - hepatic toxicity
Referenzen
- 1
Babatin M, Lee S S, Pollak P T.
Amiodarone hepatotoxicity.
Curr
Vasc Pharmacol.
2008;
6
228-236
MissingFormLabel
- 2
Brien J F, Jimmo S, Brennan F J, Ford S E, Armstrong P W.
Distribution of amiodarone and its metabolite,
desethylamiodarone, in human tissues.
Can J Physiol Pharmacol.
1987;
65
360-364
MissingFormLabel
- 3
Chang C C, Petrelli M, Tomashefski Jr J F, McCullough A J.
Severe intrahepatic cholestasis caused by amiodarone toxicity
after withdrawal of the drug: a case report and review of the literature.
Arch Pathol Lab Med.
1999;
123
251-256
MissingFormLabel
- 4
Flaharty K K, Chase S L, Yaghsezian H M, Rubin R.
Hepatotoxicity
associated with amiodarone therapy.
Pharmacotherapy.
1989;
9
39-44
MissingFormLabel
- 5
Fogoros R N, Anderson K P, Winkle R A, Swerdlow C D, Mason J W.
Amiodarone: clinical efficacy
and toxicity in 96 patients with recurrent, drug-refractory arrhythmias.
Circulation.
1983;
68
88-94
MissingFormLabel
- 6 Gassanov N, Dietlein M, Caglayan E, Erdmann E, Er F. Amiodaron-induzierte Schilddrüsenfunktionsstörungen. Dtsch Med Wochenschr; 2010 135: 807-811
MissingFormLabel
- 7
Giannattasio F, Salvio A, Varriale M. et al .
Three cases of severe acute hepatitis after
parenteral administration of amiodarone: the active ingredient is
not the only agent responsible for hepatotoxicity.
Ann Ital
Med Int.
2002;
17
180-184
MissingFormLabel
- 8
Guigui B, Perrot S, Berry J P. et al .
Amiodarone-induced hepatic phospholipidosis:
a morphological alteration independent of pseudoalcoholic liver
disease.
Hepatology.
1988;
8
1063-1068
MissingFormLabel
- 9
Gundling F, Tillmann H L, Schmidt O. et al .
Severe intrahepatic cholestasis in a 66-year
old male patient with medically treated atrial fibrillation.
Internist
(Berl).
2005;
46
1038-1042
MissingFormLabel
- 10
Kum L C, Chan W W, Hui H H. et al .
Prevalence of amiodarone-related hepatotoxicity
in 720 Chinese patients with or without baseline liver dysfunction.
Clin Cardiol.
2006;
29
295-299
MissingFormLabel
- 11
Lee W M.
Acute liver failure in the United States.
Semin Liver
Dis.
2003;
23
217-226
MissingFormLabel
- 12
Lee W M.
Drug-induced hepatotoxicity.
N Engl J Med.
2003;
349
474-485
MissingFormLabel
- 13
Lewis J H, Mullick F, Ishak K G. et al .
Histopathologic analysis of suspected amiodarone
hepatotoxicity.
Hum Pathol.
1990;
21
59-67
MissingFormLabel
- 14
Lewis J H, Ranard R C, Caruso A. et al .
Amiodarone hepatotoxicity: prevalence and
clinicopathologic correlations among 104 patients.
Hepatology.
1989;
9
679-685
MissingFormLabel
- 15
Munoz Ruiz A I, Calvo Elipe A, Guerrero Vega E. et al .
Pancreatitis and inappropriate ADH secretion
syndrome associated with amiodarone.
An Med Interna.
1996;
13
125-126
MissingFormLabel
- 16
Raja K, Thung S N, Fiel M I, Chang C.
Drug-induced steatohepatitis
leading to cirrhosis: long-term toxicity of amiodarone use.
Semin
Liver Dis.
2009;
29
423-428
MissingFormLabel
- 17
Rinder H M, Love J C, Wexler R.
Amiodarone hepatotoxicity.
N Engl J Med.
1986;
314
318-319
MissingFormLabel
- 18
Sastri S V, Diaz-Arias A A, Marshall J B.
Can pancreatitis be associated with
amiodarone hepatotoxicity?.
J Clin Gastroenterol.
1990;
12
70-73
MissingFormLabel
Dr. Natig Gassanov
Herzzentrum Köln, Klinik III für
Innere Medizin
Kerpener Str. 62
50924 Köln
Phone: 0221/47832544
Email: Natig.Gassanov@uk-koeln.de